Here's Why You Should Add Accuray Stock in Your Portfolio Now

Accuray Incorporated ARAY is well-poised for growth in the coming quarters, courtesy of continued robust demand for its products. The optimism, led by robust international performance in the first quarter of fiscal 2025 and potential in the Radiosurgery Market, is expected to contribute further. However, reimbursement uncertainties and macroeconomic instability are concerning.This Zacks Rank #2 (Buy) company has lost 26.2% in the year-to-date period against 6.2% growth of the industry. The S&P 500 has witnessed 28.1% growth in the said time frame.The renowned radiation oncology company has a market capitalization of $202.1 million. Accuray projects 106.3% growth for fiscal 2025 and expects to maintain its strong performance going forward. The company has a P/S ratio of 0.5 compared with the industry’s 3.1.Image Source: Zacks Investment ResearchReasons Favoring Accuray’s GrowthPotential in Radiosurgery Market: Accuray’s CyberKnife System is a robotic radiosurgery system capable of treating tumors throughout the body. An extensive body of published literature supports its use in the treatment of various targets, including cancers, benign tumors, or functional diseases. With more than two decades of clinical evidence, the CyberKnife System offers distinct advantages in the treatment of diseases in the head, base of the skull, and spine.During the fiscal first quarter, management commented on the strong customer adoption of the CyberKnife system. Per management, customer installation activity of both the CyberKnife and Radixact systems was robust during the first quarter of fiscal 2025, with 22% growth in new customers installed year over year. By achieving above-market new order growth, the China backlog funnel was also built.Rising Product Demand in China:  Accuray is witnessing improved customer reception of its technologies globally. Tomo C system is likely to expand ARAY’s product portfolio in China, allowing ARAY to compete in the largest and fastest-growing segment of the China radiotherapy market. Tomo C system received final regulatory approvals during the fourth quarter of fiscal 2024.Management also commented on the China team's ability to ramp up manufacturing production of the Tomo C systems at the Tianjin facility. Per management, these systems are likely to ship over the next several quarters based on customer timing, with the majority expected in the fiscal second quarter through the fiscal fourth quarter.Strong International Revenue Growth: Accuray’s products have registered robust customer adoption over the past few months. During the fiscal first quarter, Accuray witnessed impressive demand for its products in China, delivering significant revenue growth of 30% year over year.Per the fiscal first-quarter earnings call, the customer base grew 4% year over year in EIMEA (Europe, India, the Middle East and Africa) and 3% in Japan in the quarter, which is likely to increase the installed base in those regions and drive future recurring service and upgrade revenue opportunities. The company expects both regions to show stronger revenue growth in the second half of fiscal 2025, driven by visibility to customer timing and additional commercial coverage.Factors That May Offset the Gains for ARAYMacroeconomic Instability: Accuray’s business is materially affected by global market conditions and the overall economy. Additionally, uncertain credit markets and apprehensions regarding the availability of credit, including concerns related to the pandemic, could impact consumer and customer demand for Accuray’s products and its ability to manage normal commercial relationships with its customers, suppliers and creditors. If the current situation deteriorates or does not improve, the company’s business could be affected by factors such as reduced demand for its products resulting from a slowdown or volatility in the general economy, among others.Reimbursement Uncertainties: Accuray’s customers rely significantly on reimbursement from public and private third-party payors for the CyberKnife and TomoTherapy platform procedures. The company’s ability to commercialize its products successfully and increase market acceptance of the same will significantly depend on the extent to which public and private third-party payors provide adequate coverage and reimbursement for procedures that are performed with Accuray’s products and the extent to which patients who are treated by its products continue to be covered by health insurance. Third-party payors may establish or change the reimbursement for medical products and services that could significantly influence the purchase.Estimate TrendAccuray has been witnessing a stable estimate revision trend for fiscal 2025. Over the past 30 days, the Zacks Consensus Estimate for earnings has remained stable at earnings of 1 cent per share.The Zacks Consensus Estimate for second-quarter fiscal 2025 revenues is pegged at $110.9 million, suggesting a 3.5% improvement from the year-ago reported number.Other Key PicksSome other top-ranked stocks in the broader medical space are Masimo MASI, AngioDynamics ANGO and AxoGen AXGN.Masimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 11.8% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Its shares have risen 48.6% compared with the industry’s 6.4% growth year to date.AngioDynamics, carrying a Zacks Rank #2 at present, has an estimated growth rate of 38.2% for 2025. ANGO’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 31.71%.AngioDynamics’ shares have lost 8.9% year to date against the industry’s 6.7% growth.AxoGen, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 252% for 2025. It delivered a trailing four-quarter average earnings surprise of 91.11%.AXGN’s shares have risen 111.4% year to date compared with the industry’s 6.4% growth.Zacks Naming Top 10 Stocks for 2025Want to be tipped off early to our 10 top picks for the entirety of 2025?History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Accuray Incorporated (ARAY): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report AxoGen, Inc. (AXGN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks